KSE - Delayed Quote KRW

JW Lifescience Corporation (234080.KS)

11,950.00
+50.00
+(0.42%)
At close: 3:30:30 PM GMT+9
Currency in KRW All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
222,478,095.66
222,478,095.66
206,860,371.79
188,931,165.24
169,816,950.01
Cost of Revenue
164,970,427.65
164,970,427.65
154,467,347.22
140,810,465.26
120,659,669.94
Gross Profit
57,507,668.01
57,507,668.01
52,393,024.57
48,120,699.98
49,157,280.07
Operating Expense
21,649,679
21,649,679
21,531,109
21,031,446
20,740,570
Operating Income
35,857,989.01
35,857,989.01
30,861,915.57
27,089,253.98
28,416,710.07
Net Non Operating Interest Income Expense
-554,833.04
-554,833.04
-1,573,465.71
-2,005,132.47
-1,150,987.97
Pretax Income
59,026,503.79
59,026,503.79
33,708,268.58
20,781,845.01
18,287,103.23
Tax Provision
15,038,972.79
15,038,972.79
5,564,302.17
5,820,578.16
5,373,484.09
Net Income Common Stockholders
43,987,530.99
43,987,530.99
28,143,966.40
14,961,266.84
12,913,619.14
Basic EPS
2.84k
--
1.82k
966.00
829.00
Diluted EPS
2.84k
--
1.82k
966.00
829.00
Basic Average Shares
15,483.12
--
15,480.73
15,487.85
15,577.35
Diluted Average Shares
15,483.12
--
15,480.73
15,487.85
15,577.35
Total Operating Income as Reported
35,857,988.75
35,857,988.75
30,861,915.61
27,089,253.52
28,416,710.56
Rent Expense Supplemental
1,517,990
1,517,990
1,024,151
123,189
170,581
Total Expenses
186,620,106.65
186,620,106.65
175,998,456.22
161,841,911.26
141,400,239.94
Net Income from Continuing & Discontinued Operation
43,987,530.99
43,987,530.99
28,143,966.40
14,961,266.84
12,913,619.14
Normalized Income
32,667,584.88
32,667,584.88
29,743,190.21
15,282,300.79
16,269,674.47
Interest Income
1,505,763
1,505,763
1,130,352
1,086,802
130,358
Interest Expense
2,060,596
2,060,596
2,693,103
3,091,935
1,281,346
Net Interest Income
-554,833.04
-554,833.04
-1,573,465.71
-2,005,132.47
-1,150,987.97
EBIT
61,087,099.79
61,087,099.79
36,401,371.58
23,873,780.01
19,568,449.23
EBITDA
76,824,243.79
76,824,243.79
51,932,074.58
38,829,871.01
32,813,202.23
Reconciled Cost of Revenue
164,970,427.65
164,970,427.65
154,467,347.22
140,810,465.26
120,659,669.94
Reconciled Depreciation
15,737,144
15,737,144
15,530,703
14,956,091
13,244,753
Net Income from Continuing Operation Net Minority Interest
43,987,530.99
43,987,530.99
28,143,966.40
14,961,266.84
12,913,619.14
Total Unusual Items Excluding Goodwill
15,190,142
15,190,142
-1,915,404
-445,930
-4,752,543
Total Unusual Items
15,190,142
15,190,142
-1,915,404
-445,930
-4,752,543
Normalized EBITDA
61,634,101.79
61,634,101.79
53,847,478.58
39,275,801.01
37,565,745.23
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
3,870,195.89
3,870,195.89
-316,180.19
-124,896.05
-1,396,487.67
12/31/2021 - 10/27/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SMDPY Sumitomo Pharma Co., Ltd.
4.7800
0.00%
 
000020.KS Dongwha Pharm.Co.,Ltd
6,400.00
+1.59%
 
069620.KQ 069620.KQ,0P0000BXZW,24919
118,200.00
-0.84%
 
019170.KS Shinpoong Pharmaceutical Co.,Ltd
7,440.00
+0.68%
 
001060.KS JW Pharmaceutical Corporation
22,200.00
+1.14%
 
003090.KS Daewoong Co., Ltd.
20,100.00
+1.46%
 
DNPUF Sumitomo Pharma Co., Ltd.
6.53
0.00%
 
128940.KS Hanmi Pharm. Co., Ltd.
288,500.00
+4.15%
 
068760.KQ Celltrion Pharm, Inc.
47,300.00
+0.64%
 
006280.KS GC Biopharma Corp.
121,300.00
+1.17%